1. INTRODUCTION {#acm212527-sec-0002}
===============

The application of VMAT to left breast irradiation has raised concern about potential cardiac toxicity. Respiratory gating techniques such as voluntary deep inspiration breath‐hold (DIBH), which has been shown to protect the heart by displacing it from the chest wall, are not available at many institutions.[1](#acm212527-bib-0001){ref-type="ref"}, [2](#acm212527-bib-0002){ref-type="ref"} VMAT and intensity‐modulated radiotherapy (IMRT) with built‐in skin flash may decrease the heart dose but increase low‐dose exposure of nearby healthy tissues compared with three‐dimensional (3D) field‐in‐field tangents.[3](#acm212527-bib-0003){ref-type="ref"}, [4](#acm212527-bib-0004){ref-type="ref"}, [5](#acm212527-bib-0005){ref-type="ref"}, [6](#acm212527-bib-0006){ref-type="ref"}, [7](#acm212527-bib-0007){ref-type="ref"}, [8](#acm212527-bib-0008){ref-type="ref"}, [9](#acm212527-bib-0009){ref-type="ref"} Selected cases have been presented where our radiation oncologists have requested VMAT to spare large volumes of the heart from receiving prescription dose. While a proportional increase in ischemic heart disease has been linked with the heart mean dose, it is not known if it is better for less of the heart to receive a high dose or more of the heart to receive a low dose.[10](#acm212527-bib-0010){ref-type="ref"}, [11](#acm212527-bib-0011){ref-type="ref"}, [12](#acm212527-bib-0012){ref-type="ref"} The use of VMAT with integrated skin flash has been clinically accepted by our physicians. This study quantifies the dosimetric trade‐offs and crossover points between low‐ and high‐dose volumes for left breast cancer patients treated with the VMAT with the integrated skin flash planning method compared to results obtained using conventional 3D planning techniques.

2. MATERIALS AND METHODS {#acm212527-sec-0003}
========================

Left breast radiotherapy plans were compared for traditional 3D field‐in‐field tangent plans and four partial arcs VMAT using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA).

2.A. Patient selection {#acm212527-sec-0004}
----------------------

The study included nine consecutive left breast cancer patients without axillary lymph nodes involvement who were treated in the supine position without respiratory gating or voluntary breath hold by a single radiation oncologist. The physician requested eight patients be planned and treated using VMAT and one be planned and treated using 3D field‐in‐field tangents. Patients were prescribed 4256 cGy to their entire left breast in 16 fractions of 266 cGy each. Patient data sets were transferred to MIM Maestro (MIM Software Inc, Cleveland, OH) for image registration if PET is requested and organs at risk (OAR) delineation. The physician specified the planned target volume and approved the OAR contours.

2.B. Treatment planning {#acm212527-sec-0005}
-----------------------

Two plans were created for each patient utilizing field‐in‐field tangents and VMAT with included flash. Figure [1](#acm212527-fig-0001){ref-type="fig"} shows the typical isodose distributions achieved using each method for the same patient. The VMAT plans utilized four 6 MV partial arcs rotating from gantry 180°‐300°, with the endpoint varying ±10° depending on patient anatomy. The collimator was set to ±30° to avoid the overlapping tongue and groove effect and the X‐jaw positions were defined to prevent the maximum X‐jaw motion from exceeding 14.5 cm to allow full MLC modulation of the field. Maximum leaf travel and the field width necessitated the use of four arcs to allow sufficient modulation of the entire field width. To accommodate skin flash, plans were optimized with 1 cm of bolus of 0.6 g/cm^3^ and an optimization PTV that was expanded 8 mm anteriorly to simulate the chest motion.[13](#acm212527-bib-0013){ref-type="ref"} All optimizations were performed with the bolus linked to the fields. The bolus was removed on the final dose calculation to simulate treatment conditions. After the final dose calculation, plans were normalized to cover 95% of the physician\'s original target volume with 100% prescription dose.

![Left panel is a volumetric modulated arc therapy plan optimized to meet the constraints set by the physician, and the right panel is a three‐dimensional field‐in‐field plan with tangents placed to encompass the left breast while maximizing sparing of the ipsilateral lung, heart, and contralateral breast.](ACM2-20-24-g001){#acm212527-fig-0001}

Three‐dimensional field‐in‐field plans utilized non‐divergent tangents of mixed energies to optimize homogeneity. Tangent angles were chosen to minimize dose to the heart, ipsilateral lung, and contralateral breast while still covering the target volume. MLC‐defined control points were created to minimize hot spots and improve homogeneity.

Figure [2](#acm212527-fig-0002){ref-type="fig"} illustrates the VMAT and 3D field arrangements. A 2 mm dose grid was applied to all cases and the AcurosXB dose calculation was used (Varian Medical Systems, Palo Alto, CA).

![Beam arrangement for (a) volumetric modulated arc therapy using four arcs and (b) three‐dimensional field‐in‐field using non‐divergent tangents with flash.](ACM2-20-24-g002){#acm212527-fig-0002}

Pre‐treatment imaging was performed as requested by the physician, with the routine CBCT to confirm that the breast was within the optimized treatment volume and swelling or respiratory motion had not exceeded the planned motion.

2.C. Analysis {#acm212527-sec-0006}
-------------

To quantify both the expected increase in low‐dose scatter by VMAT and volume of prescription dose to nearby critical structures by 3D field‐in‐field plans, the heart, contralateral lung, and contralateral breast were evaluated based on the mean dose and relative volume receiving 5% (V5), 10% (V10), 20% (V20), 30% (V30), 40% (V40), and 100% (V100) of the prescription dose. Homogeneity index (HI) was calculated to evaluate dose uniformity within the target using:$$HI = \frac{D_{2} - D_{98}}{D_{p}} \times 100$$where *D* ~2~ = minimum dose to 2% of the target volume, *D* ~98~ = minimum dose to 98% of the target volume, and *D* ~p~ = prescribed dose.[14](#acm212527-bib-0014){ref-type="ref"} Using this index, a lower HI value indicates a more homogenous dose distribution.

3. RESULTS {#acm212527-sec-0007}
==========

Table [1](#acm212527-tbl-0001){ref-type="table"} shows the minimum, maximum, mean, and standard deviations for all criteria evaluated for both VMAT and 3D field‐in‐field delivery techniques. The VMAT plan produced a higher overall mean dose and V5, V10, and V20 for the heart, contralateral lung, and contralateral breast in every patient. The volume of the contralateral breast and heart receiving the prescription dose was slightly lower in the VMAT plans, but not statistically significant. Treatment method did not significantly affect the volume of contralateral lung receiving the prescription dose. VMAT provided superior homogeneity, with a mean homogeneity index of 9.41 ± 1.64 for VMAT compared to 11.05 ± 1.82 for 3D field‐in‐field tangents.

###### 

Results for plan evaluation criteria for each organ at risk. Values reported as 0.000 are less than 0.001

  Structures             Minimum   3D field‐in‐field   SD       Minimum   VMAT     SD       *P* Value            
  ---------------------- --------- ------------------- -------- --------- -------- -------- ----------- -------- -------
  Heart                                                                                                          
  Mean (cGy)             49.2      910.1               399.53   260.14    192.9    961.5    747.53      249.44   0.011
  V5 (%)                 1.85      34.53               22.66    12.12     32.06    100      90.65       22.55    0
  V10 (%)                0.04      25.09               11.6     8.42      10.33    96.75    77.74       29.36    0
  V20 (%)                0         21.75               8.75     7.13      0.35     54.55    33.36       17.54    0.002
  V30 (%)                0         20.21               7.74     6.58      0        17.17    10.48       5.93     0.245
  V40 (%)                0         19.06               7.06     6.19      0        7.47     3.77        2.54     0.291
  V100 (%)               0         12.06               3.11     4         0        0        0           0        0.066
  Contralateral lung                                                                                             
  Mean (cGy)             17.7      51.5                31.93    12.01     193.7    436.5    299.82      70.13    0.000
  V5 (%)                 0         2.76                0.89     1.05      29.58    98.67    66.78       20.12    0.000
  V10 (%)                0         0.95                0.16     0.31      7.31     39.35    17.62       9.85     0.001
  V20 (%)                0         0.36                0.05     0.12      0.09     4.48     1.38        1.73     0.05
  V30 (%)                0         0.21                0.02     0.07      0        0.77     0.1         0.25     0.424
  V40 (%)                0         0.14                0.02     0.05      0        0.19     0.02        0.06     0.838
  V100 (%)               0         0                   0        0         0        0        0           0        \*
  Ipsilateral lung                                                                                               
  Mean (cGy)             188.79    871.42              573.71   195.78    234.08   891.42   674.58      192.37   0.288
  V5 (%)                 19.52     42.50               33.26    7.59      8.3      99.95    82.87       29.48    0.001
  V10 (%)                11.99     31.42               23.66    6.3       7.93     95.18    67.1        28.26    0.003
  V20 (%)                6.3       24.42               17.15    5.57      7.12     36.61    25.39       9.83     0.048
  V30 (%)                3.88      22.19               14.57    5.24      4.19     20.8     13.09       4.4      0.532
  V40 (%)                2.69      20.86               13.13    5.18      0.88     14.36    8.26        3.98     0.041
  V100 (%)               0         10.45               2.44     3.28      0        0.17     0.03        0.06     0.105
  Contralateral breast                                                                                           
  Mean (cGy)             94.1      799.1               305.76   282.21    248.9    738.4    422.87      159.11   0.298
  V5 (%)                 5.75      28.95               13.42    9.04      33.36    85.95    67.49       17.52    0
  V10 (%)                2.48      21.22               8.26     7.72      11.88    51.37    28.2        13.94    0.003
  V20 (%)                1.64      19.21               6.86     7.19      2.97     24.89    9.6         8.04     0.458
  V30 (%)                0.93      18.15               6.18     6.83      0.64     16.2     4.79        5.48     0.641
  V40 (%)                0.5       17.33               5.68     6.54      0.04     11.13    2.73        3.88     0.266
  V100 (%)               0         9.9                 2.86     3.99      0        0.06     0.01        0.02     0.064
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Figure [3](#acm212527-fig-0003){ref-type="fig"} shows the mean, minimum, and maximum DVH curves for each evaluated structure with the VMAT and 3D field‐in‐field plans. The intersection point for the mean DVH curves was calculated for each structure.

![The maximum, minimum, and mean DVH curves for (a) PTV, (b) heart, (c) contralateral lung, (d) ipsilateral lung, and (e) contralateral breast.](ACM2-20-24-g003){#acm212527-fig-0003}

3.A. PTV coverage and homogeneity {#acm212527-sec-0008}
---------------------------------

All plans were normalized to cover 95% of the PTV with 100% prescription dose. The average *D* ~2~ was 4583.15 ± 55.52 cGy for VMAT and 4649.59 ± 70.40 cGy for 3D field‐in‐field tangents. VMAT also produced a better *D* ~98~ of 4182.71 ± 22.27 cGy compared to 4179.32 ± 12.79 cGy for 3D field‐in‐field tangents. Therefore, the HI was smaller for VMAT, meaning it produced a more homogeneous plan with a value of 9.41 ± 1.64 vs 11.05 ± 1.82 for 3D field‐in‐field.

3.B. Heart {#acm212527-sec-0009}
----------

VMAT decreased the V100 and V40 volumes as compared to field‐in‐field, but at the cost of increasing the V5, V10, V20, V30, and mean dose. The mean DVH curve for VMAT was higher than the field‐in‐field curve for doses up to 34.18% of the prescription dose (1454.70 cGy). At higher doses, the mean field‐in‐field curve was higher.

3.C. Contralateral lung {#acm212527-sec-0010}
-----------------------

Mean dose and V5, V10, and V20 were higher with VMAT plans than with field‐in‐field for the contralateral lung. The mean DVH curve for VMAT was higher than the field‐in‐field curve for doses up to 27.15% of the prescription dose (1155.50 cGy). At higher doses, the mean field‐in‐field curve was higher.

3.D. Ipsilateral lung {#acm212527-sec-0011}
---------------------

Ipsilateral lung mean dose, V5, V10, and V20 were higher, but V30, V40, and V100 were lower with VMAT plans. The mean DVH curve for VMAT was higher than the field‐in‐field curve for doses up to 28.78% of the prescription dose (1012.08 cGy). At higher doses, the mean field‐in‐field curve was higher.

3.E. Contralateral breast {#acm212527-sec-0012}
-------------------------

The average mean dose and V5, V10, and V20 were higher with VMAT compared to field‐in‐field for the contralateral breast. The mean DVH curve for VMAT was higher than the field‐in‐field curve for doses up to 23.13% of the prescription dose (984.75 cGy). Above this dose, the mean field‐in‐field curve was higher.

4. DISCUSSION {#acm212527-sec-0013}
=============

Three‐dimensional field‐in‐field produces lower mean doses and V5, V10, and V20 for the heart, contralateral lung, and contralateral breast than VMAT due to the low‐dose spread of VMAT. 3D field‐in‐field plans did, however, show a slight increase in relative volume receiving the prescription dose for the contralateral breast and heart but was not statistically significant. There was no difference between the two methods in the contralateral lung. VMAT produces superior homogeneity, with a mean value of 9.41 ± 1.64 compared to 11.05 ± 1.82 for field‐in‐field. VMAT also resulted in a lower *D* ~2~ to the targeted breast, which may result in less desquamation and fibrosis, and to the contralateral breast, which may result in fewer radiation‐induced breast cancers. Hot spots were minimized by the planner as low as achievable, being limited by the superficial skin and target volume coverage deemed acceptable by the physician.

The crossover point for the mean DVH curves provides an estimate for the dose level above which VMAT is beneficial. The mean DVH curves for heart, contralateral lung, ipsilateral lung, and contralateral breast were all higher in the low‐dose region for VMAT, crossing the mean 3D field‐in‐field curve between 23.13% and 34.18% of the prescription dose (984.75‐1454.70 cGy). Therefore, if the clinician is primarily interested in the mean dose to OAR or the OAR volume receiving less than approximately 30% of the prescription, the 3D field‐in‐field tangent treatment method should be used. However, if the clinician is more concerned with the maximum dose, dose homogeneity to the target, and volumes of the OARs receiving above 30% of the prescribed dose, the VMAT treatment method will be preferred.

Given the smaller sample size of nine patients, the *P* value was computed to evaluate the significance of the results. As seen in Table [1](#acm212527-tbl-0001){ref-type="table"}, the significance of the results varies for parameter evaluated. However, the mean dose and low‐dose volume of the heart and the low‐dose volume of both ipsilateral and contralateral lung were statistically significant. The trends presented by the maximum, minimum, and mean data were observed in all cases on a head‐to‐head plan analysis. All VMAT plans utilized the same treatment planning technique, different from other documented VMAT breast planning methods.[3](#acm212527-bib-0003){ref-type="ref"}, [5](#acm212527-bib-0005){ref-type="ref"} Despite the different planning technique, our study produces comparable results while further quantifying the dosimetric trade‐offs between VMAT and 3D field‐in‐field tangents.[5](#acm212527-bib-0005){ref-type="ref"}

5. CONCLUSIONS {#acm212527-sec-0014}
==============

VMAT radiotherapy is used for treatment of left breast in numerous centers. While respiratory gating and the use of voluntary DIBH have been shown to reduce heart dose, it is not yet available in many centers. This study evaluated a method of using VMAT incorporating skin flash that can easily be implemented in the Eclipse TPS by applying bolus to the optimization process. Among patients whose entire left breast was treated in the supine position with free‐breathing, VMAT spared the heart, contralateral lung, and contralateral breast from prescription dose, delivered a more homogenous dose distribution to the targeted breast, and decreased the maximum breast dose compared to an optimized 3D field‐in‐field tangent treatment technique. However, VMAT produced higher mean and low‐dose volumes to the organs at risk. The crossover value of the mean DVH curves occurred at 23.13%‐34.18% of the prescription dose. In comparison with a 3D‐conformal technique, VMAT improves dose homogeneity and high‐dose exposure of OARs at the expense of mean OAR dose and OAR volume receiving less than approximately 30% of the prescription dose.
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